Curative Biotechnology, Inc. (CUBT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Palm Beach Gardens, FL, アメリカ. 現CEOは I. Richard Garr.
CUBT を有する IPO日 1998-03-30, 4 名の正社員, に上場 Other OTC, 時価総額 $7.87M.
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
